Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 7 of 23

TERMINATED NA

Perioperative Continuous Glucose Monitoring

NCT05937373

COMPLETED NA

Pilot Trial of an Online Pain Coping Skills Training Program in Spanish

NCT05917171

COMPLETED

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

NCT05857007

COMPLETED NA

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery

NCT05820139

TERMINATED

BurstDR Stimulation for Painful Diabetic Neuropathy

NCT05985291

COMPLETED NA

Dragon Ambient eXperience (DAX) Copilot Evaluation

NCT06329427

COMPLETED NA

Telemedicine Management of Hypertension

NCT05424744

COMPLETED NA

A Study of Hookah Café Customers in the Atlanta Area

NCT05916170

COMPLETED NA

Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)

NCT05800145

COMPLETED NA

Rural Area Pharmacist Intervention for Diabetes

NCT05761886

TERMINATED Phase 2

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

NCT05597878

COMPLETED NA

Auricular Acupressure as a Non-Opioid Adjuvant in Opioid Tolerant Patients

NCT05711537

COMPLETED Phase 4

Pecto-intercostal Fascial Block (PIFB) for Postop Analgesia Following Sternotomy in Cardiac Surgery Patients

NCT05676814

TERMINATED Phase 4

RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients

NCT05386368

COMPLETED NA

Food Addiction Clinical Treatment Program

NCT04373343

COMPLETED Phase 4

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

NCT05515562

COMPLETED NA

Arena Labs - Improving Clinician Well Being

NCT05653700

COMPLETED NA

Comparison of Text and Pictorial Waterpipe Tobacco Warnings Among Young Adults

NCT05783843

COMPLETED Phase 4

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

NCT05742841

COMPLETED

Tourette Discrimination (TD) Stigma Scale

NCT05696769

COMPLETED NA

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX) - Atrium Health

NCT05746520

COMPLETED Phase 1

A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects

NCT05672667

COMPLETED NA

Steps for Epilepsy

NCT05359003

COMPLETED NA

COVID-19 Testing and Vaccination Among Spanish Speakers

NCT05302908

COMPLETED NA

Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model

NCT05413889

COMPLETED Early Phase 1

The Effects of Sedatives on Tobacco Use Disorder Version 2

NCT05505630

COMPLETED NA

Monocyte Priming When Consuming a Western Diet

NCT05348395

COMPLETED

Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy

NCT05490875

COMPLETED Phase 4

Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate

NCT05661942

COMPLETED Phase 1

Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients

NCT05537883

COMPLETED NA

Quantifying the Venous Congestion Curve of a Tissue Oximetry Device

NCT05592145

COMPLETED NA

Consumer Perceptions of Waterpipe Tobacco Packaging and Digital Marketing Claims

NCT05439421

COMPLETED NA

Telehealth-Enhanced Assessment and Management After Stroke-Blood Pressure

NCT05539443

TERMINATED NA

Mastectomy Flap Temperature Study

NCT05395936

COMPLETED NA

Trial of the Impact of the Electronic Frailty Integrated With Social Needs

NCT05293730

COMPLETED NA

Effects of Smoking State on Decision Making

NCT04826276

COMPLETED NA

Cranial Ultrasound for Prehospital ICH Diagnosis

NCT05492474

COMPLETED NA

Adolescents Living With HIV (ALWH): Social Networks, Adherence and Retention

NCT04077047

COMPLETED

Child Health Improvement Through Computer Automation - Child Neurology (CHICA-CN) Evaluation

NCT05173506

COMPLETED NA

Improving Disease Severity

NCT05391178

COMPLETED NA

Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM)

NCT05320887

COMPLETED NA

A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

NCT05759338

TERMINATED NA

The Effects of Animal Assisted Therapy in Outpatient Psychiatry Clinics

NCT05326074

COMPLETED NA

Health, Aging and Later-Life Outcomes

NCT05424042

TERMINATED NA

At Home Early vs. Delayed Catheter Removal Following Failed Postoperative Voiding Trial: a Randomized Trial

NCT05353400

COMPLETED NA

Radiofrequency Hyperthermia Safety Study

NCT05399771

COMPLETED Phase 4

PENG Block Versus LP Block for THA Postop Pain

NCT05261009

COMPLETED NA

Expanding Health System Intervention Through The Women, Infants and Children (WIC) Program Partnership

NCT05356338

COMPLETED NA

Well-Child Visit Trial

NCT05086237

COMPLETED Phase 2

Dose Ranging Study of Intravenous Oxytocin for Analgesia to Heat Pain

NCT05179421

← Previous Page 7 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.